Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt remains negative

Q1 FY2026 net debt was -$72.7M, compared with -$74.82M a year earlier.

Context

  • Net debt amounted to 18.0% of total assets at the end of Q1 FY2026, up 5.1 pp from a year earlier.
  • Net debt grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +2.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$72.7M+15.1% QoQ
Last fiscal yearDec 2025
-$85.65M-5.9% YoY
Year agoMar 2025
-$74.82M+2.8% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.8%——
1 year-5.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(85.65M) USD
Year-over-year change
-5.9%

Net Debt vs competitors

How CGEM compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +2.8% is the 4th highest of 11, against a peer median of -25.9%.
  • Net debt amounts to 18.0% of total assets for CGEM, versus a peer median of 16.3%.
CGEM Competitors
Net Debt for CGEM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
XNCRXencor, Inc.Jun 2026$20.55M USD-12.5%+186.4%2.8%
CGENCompugen Ltd.Mar 2026-$9.5M USD+19.5%—6.5%
ALXOALX Oncology Holdings Inc.Mar 2026-$27.07M USD-154.3%—15.2%
MGNXMacroGenics, Inc.Mar 2026-$30.01M USD+72.2%—13.8%
JANXJanux Therapeutics, Inc.Mar 2026-$30.26M USD+40.8%—2.9%
AVBPArriVent BioPharma, Inc. Common StockMar 2026-$61.68M USD-24.0%—17.7%
CGEMCullinan Therapeutics, Inc.Mar 2026-$72.7M USD+2.8%—18.0%
ADCTADC Therapeutics S.A.Mar 2026-$114.34M USD-144.8%—39.2%
IMTXImmatics N.V.Mar 2026-€286.55M EUR-27.7%—52.7%
LEGNLegend Biotech CorporationSep 2026-$293.3M USD-323.3%—17.4%
NRIXNurix Therapeutics, Inc.Aug 2026-$654.91M USD-2883.4%—54.8%
Peer median (excluding CGEM) —-25.9%+186.4%16.3%

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents59.77M156.15M98.43M83.01M88.33M
Short-term Investments230.69M311.14M368.63M315.97M289.56M
Net Receivables0003M0
Inventory00000
Other Current Assets07.18M13.12M12.69M8.86M
Total Current Assets296.56M474.47M480.19M414.67M386.76M
Property, Plant & Equipment (Net)77K5.3M3.53M2.35M3.05M
Goodwill00000
Intangible Assets00000
Long-term Investments140.4M80.88M0204.44M58.27M
Tax Assets00000
Other Non-current Assets147K459K459K366K297K
Total Non-current Assets140.62M86.65M3.99M207.16M61.62M
Total Assets437.19M561.12M484.18M621.82M448.37M
Account Payables3.17M2.66M2.49M1.68M841K
Short-term Debt0178K000
Tax Payables04.28M000
Deferred Revenue00000
Other Current Liabilities3.55M1.96M7.9M1.44M10.95M
Total Current Liabilities11.75M22.5M28.14M30.65M37.74M
Long-term Debt00001.9M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities65K0000
Total Non-current Liabilities65K3.59M2.15M849K1.9M
Total Liabilities11.81M26.09M30.29M31.5M39.64M
Common Stock4K5K4K6K6K
Retained Earnings(158.91M)(47.7M)(200.86M)(368.24M)(588.12M)
Accumulated OCI(838K)(2.6M)(129K)(133K)1.02M
Other Stockholders Equity00000
Minority Interest403K0192K00
Total Equity425.37M535.03M453.9M590.33M408.73M
Total Debt05.19M3.59M2.15M2.68M
Net Debt(59.77M)(150.96M)(94.84M)(80.85M)(85.65M)

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.